Current Headlines

  1. Lilly Posts Positive Trial Results For Cyramza In Gastric Cancer
    9/22/2014

    Eli Lilly & Co. announced positive results from the global Phase 3 trial of Cyramza (ramucirumab) in combination with paclitaxel in patients with advanced gastric (stomach) cancer or gastroesophageal junction (GEJ) adenocarcinoma.

  2. Bayer To Focus On Life Sciences, Splits Off MaterialScience Business
    9/22/2014

    Bayer announced it plans to devote its full attention to its Life Science businesses, which includes HealthCare and CropScience, and to float its MaterialScience plastics business on the stock market in 2016 as a separate entity.

  3. Relmada And MSKCC Partner In Opioid Painkiller Studies
    9/22/2014

    Clinical stage firm Relmada Therapeutics announced that it has partnered with Memorial Sloan Kettering Cancer Center (MSKCC) to launch several animal studies of levorphanol for chronic pain.

  4. Epirus’s Biosimilar Arthritis Drug Wins Approval In India
    9/22/2014

    Boston-based biotech firm, Epirus Biopharmaceuticals, has received final marketing and manufacturing approvals from India’s drug regulators for its Remicade (infliximab) biosimilar, BOW015, making it the first infliximab biosimilar approved in India.

  5. New Chronic Lymphocytic Leukemia Therapy Enters Phase 1 Trial`
    9/19/2014

    Researchers at the University of California, San Diego School of Medicine have just moved their novel monoclonal antibody called cirmtuzumab (UC-961) into a phase 1 human clinical trial for treating chronic lymphocytic leukemia (CLL).

  6. Puerto Rico To Be New Hub For HIV Vaccine R&D
    9/19/2014

    Puerto Rico is set to become the center of research and development activities for HIV/AIDS, thanks to a multi-stakeholder collaboration that will be attempting to produce a prophylactic vaccine against the infection.

  7. Pfizer, MedGenesis’ Team Up To Explore Potential Parkinson’s Treatments
    9/19/2014

    Biotech firm MedGenesis Therapeutix announced that it has agreed to grant Pfizer an exclusive, global option to license its glial cell line-derived neurotrophic factor (GDNF) protein and convection enhanced delivery (CED) technology for research as treatment for Parkinson's disease.

  8. Novo Nordisk’s Tresiba Shows Efficacy In Children With T1 Diabetes
    9/19/2014

    Novo Nordisk’s Tresiba (insulin degludec) demonstrated its effective in children aged 1 to 18 with Type 1 diabetes. The company announced results from the BEGIN YOUNG 1 trial in a press release and at a meeting of the European Association for the Study of Diabetes (EASD). The once-daily basal insulin is approved in over 30 countries but not in the U.S., as the Food and Drug Administration (FDA) has thus far declined to approve it, citing concerns regarding cardiovascular outcomes.

  9. NW Bio’s Cancer Vaccine First To Receive PIM Designation In U.K.’s Early Access Scheme
    9/19/2014

    Northwest Biotherapeutics (NW) announced that its new cancer immune therapy, DCVax-L, is the first drug to receive “Promising Innovative Medicine” (PIM) designation by the U.K.’s new “Early Access to Medicines Scheme” (EAMS). Like the U.S.’s compassionate use program, the EAMS aims to get urgently needed drug therapies to patients more quickly.

  10. Sun Pharma Licenses Merck’s Psoriasis Drug For $80M
    9/18/2014

    Merck announced that it has entered into a licensing agreement with Indian generics company Sun Pharmaceuticals for Merck’s therapeutic antibody candidate tildrakizumab as treatment for chronic plaque psoriasis.

Newsletter Signup
Newsletter Signup
By clicking Sign Me Up, you agree to our Terms and that you have read our Privacy Policy.